anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a dental composite resin comprising a pasty polymerizable composition having a polymerizable monomer containing a polymerization initiator and a blended filler comprising a spherical synthetic silica and an organic-inorganic compounded filler. CONSTITUTION: This dental composite resin comprises 10-40 pts.wt. polymerizable monomer (e.g.; urethane dimethacrylate/triethylene glycol dimethacrylate) containing a polymerization initiator and 90-60 pts.wt. blended filler consisting of a compounded filler comprising a base filler and organic and inorganic fillers. As at least one of the base filler or an inorganic filler, a spherical synthetic silica filler synthesized by a vaporized metal combustion method and having 0.1-0.4μm average particle size is used. The dental composite resin is excellent in transparency and the cured product has high mechanical strength, is easy to grind the surface, expresses a low thermal expansion coefficient and is useful for a restorative dental material for cavities, a root cap material, an artificial tooth, etc.
Provided are conjugates. In certain aspects, provided are drug conjugates that include a knottin peptide comprising an engineered loop that binds to a cell surface molecule, and an anti-microtubule agent conjugated to the knottin peptide via a linker. In some aspects, provided are drug conjugates that include a fusion protein that includes a knottin peptide comprising an engineered loop that binds to a cell surface molecule, fused to an antibody subunit or fragment thereof. Such drug conjugates further include a drug conjugated to the fusion protein. Also provided are compositions and kits that include the conjugates of the present disclosure. Methods of using the conjugates, e.g., for therapeutic purposes, are also provided.
### Teratogenic Effects:

Pregnancy Category C: Mefloquine has been demonstrated to be teratogenic in rats and mice at a dose of 100 mg/kg/day. In rabbits, a high dose of 160 mg/kg/day was embryotoxic and teratogenic, and a dose of 80 mg/kg/day was teratogenic but not embryotoxic. There are no adequate and well-controlled studies in pregnant women. However, clinical experience with mefloquine has not revealed an embryotoxic or teratogenic effect. Mefloquine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential who are traveling to areas where malaria is endemic should be warned against becoming pregnant. Women of childbearing potential should also be advised to practice contraception during malaria prophylaxis with mefloquine and for up to 3 months thereafter. However, in the case of unplanned pregnancy, malaria chemoprophylaxis with mefloquine is not considered an indication for pregnancy termination.
Carcinomas are associated with metastasis to specific organs while sparing others. Breast cancer presents with lung metastasis but rarely kidney metastasis. Using this difference as an example, we queried the mechanism(s) behind the proclivity for organ-specific metastasis. We used spontaneous and implant models of metastatic mammary carcinoma coupled with inflammatory tissue fibrosis, single-cell sequencing analyses and functional studies to unravel the causal determinants of organ-specific metastasis. Here we show that lung metastasis is facilitated by angiopoietin 2 (Ang2)-mediated suppression of lung-specific endothelial tight junction protein Claudin 5, which is augmented by the inflammatory fibrotic microenvironment and prevented by anti-Ang2 blocking antibodies, while kidney metastasis is prevented by non-Ang2-responsive Claudins 2 and 10. Suppression of Claudins 2 and 10 was sufficient to induce the emergence of kidney metastasis. This study illustrates the influence of organ-specific vascular heterogeneity in determining organotropic metastasis, independent of cancer cell-intrinsic mechanisms.
The invention discloses a traditional Chinese medicine composition for gynecology. The traditional Chinese medicine composition comprises polygonum aviculare, dragon's blood, radix rehmanniae preparata and pepper (preferentially white pepper); and rhinoceros horn, fructus cnidii and radix aconiti carmichaeli are added so that the effect is better. The invention also provides a preparation method of suppositories of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention overcomes the defects such as poor administration and insufficient absorption, can stimulate the cell activity of female genital organs from outside to inside, realizes the functions of resolving putridity and promoting granulation, arouses the natural power of the body and thoroughly restores the metabolic ability of the female organs. The traditional Chinese medicine composition effectively treats gynecological inflammation, realizes a certain treatment effect on gynecological cancer and can comprehensively adjust internal secretion and improve immunity. During the medication, the curative effect of the medicine is not influenced by any other medicines.
Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.
The present disclosure relates to VISTA modulators for the diagnosis and treatment of cancer. In particular, the present disclosure relates to compositions and methods of treatment for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are capable of antagonizing the activity of VISTA, a naturally occurring "checkpoint" protein that contributes to immune tolerance, optionally in combination with an antagonist of the second checkpoint pathway, such as PD-1. For example, the methods and compositions may be suitable for preventing and treating colon cancer or another cancer. It is shown herein that exemplary VISTA antagonists, in particular anti-VISTA antibodies, activate immune responses against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity that reduces tumor burden. In addition, additional benefits are observed when the VISTA antagonist is used in combination with a second checkpoint protein antagonist, specifically an antibody directed against the PD-1 ligand (PD-L1).
The stress that results from preterm birth, requisite acute care and prolonged physical separation in the NICU can have adverse physiological/psychological effects on both the infant and the mother. In particular, the experience compromises the establishment and maintenance of an optimal mother-infant relationship. Within the neonatal intensive care unit (NICU), parental involvement in care is necessarily superseded by the healthcare staff. Thus, a necessary but detrimental separation between mother and infant is created at a critical period when mother-infant bonding and synchrony should be developing. The physiological challenges associated with being born too soon, along with disturbances in normal mother-infant interactions are key factors underlying the risks of premature infants for a broad range of early and midlife disorders. This study aims to highlight the importance of investigating early interventions that are designed to overcome or reduce the effects of these environmental insults and challenges by implementing a randomized controlled trial of Family Nurture Intervention in the NICU. The most important source of regulatory input is through contact with the mother and her nurturing behavior. Mother-infant interactions are the foundation for the organization of the infant's neurobiological, sensory, perceptual, emotional, physical, and relational systems. The infant's responses to the mother provide critical feedback which shapes her behavior as well. There are many co-regulatory processes embedded in these synchronous and reciprocal interactions which cross neurophysiological and neurobehavioral domains. The intervention is designed to increase biologically important activities and behaviors that enhance maternally-mediated sensory experiences of preterm infants, as well as the infant-mediated sensory experiences in the mother. The investigators hypothesize that repeated engagement of the mother and her infant in the intervention's calming activities will increase the effectiveness of co-regulation and have immediate and long-term beneficial effects for both. The study is assessing the physiological and behavioral outcomes of the infants and mothers receiving Family Nurture Intervention versus Standard Care over the course of the NICU stay.
PURPOSE:To obtain the liquid cosmetic good in the extrusion of the cosmetic from a pen point used as a pen type cosmetic tool storing the cosmetic therein, giving coating marks having a masking effect to skin, and having an excellent dispersion stability. CONSTITUTION:The liquid cosmetic comprises at least a coloring agent, a water- soluble organic solvent (e.g. propylene glycol, glycerol), water and hollow resin particles. The hollow resin particles comprise resin particles having each one or several spherical empty pores in the spherical resin, are produced from the homopolymer or copolymer of (meth)acrylic acid, their esters, acrylonitrile, styrene, vinyl acetate, etc., and have a particle diameter of 0.1-30mum, preferably 0.1-2.0mum. The hollow resin particles exist in the cosmetic in a state wherein the space parts are filled with water, and exist in an empty hollow state by the evaporation of the water due to dryness after coated on skin. Thus, light is scattered with the resin layers and air in the hollow parts, and the cosmetic thereby shows a masking effect to give a white color.
FMRI using BOLD technique is an indirect and relative measure of neuronal activity and makes comparison among age groups problematic in light of known age related changes in glucose consumption and resting cerebral blood flow. In this study Arterial Spin Tagging techniques will be used to perform quantitative measures of blood flow changes during fMRI tasks. Children and adults will perform four tasks: primary sensory (photic flash), primary motor (finger tapping), and cognitive (working memory and semantic decision) tasks using parametric block designs, to account for developmental performance, using imaging parameters that allow quantitative measures of cerebral blood flow response as well as BOLD signal. Three age groups will be studied, children 8-10, 14-16, and young adults (21-28). Data will be analyzed using AFNI to identify activated areas. Further analysis will be performed using a region of interest analysis. We will compare quantitative measures at optimal performance levels. The three experimental age groups will be compared for delta rCBF and extent of activated area for each task. The study will determine age dependent changes in blood flow response during cortical activation across ages.
Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo on Day 1 and Day 29. Participants (6 to \<12 year old) will be offered an optional BD of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.
Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
The invention relates to an application of C-type natriuretic peptide in preparation of an external contraceptive and a sperm function detection reagent. According to research findings, at the time of ovulation, the C-type natriuretic peptide is expressed at the ampulla on the fertilization position of the fallopian tube, and the chemotactic movement of sperms toward ovum can be induced to finish fertilization. If the genital tract of a female mammal is added with certain amount of C-type natriuretic peptide or the C-type natriuretic peptide and the sperms are incubated, the concentration gradient distribution of C-type natriuretic peptide in the fallopian tube is changed, and the sperms cannot make chemotactic movement toward ovum along the concentration gradient so as to block fertilization. Based on the sperm chemotaxis principle, the invention provides an external contraceptive taking endogenous protein C-type natriuretic peptide as an active ingredient. The contraceptive does not cause toxic or side effects or adverse reaction, is suitable for contraception of most women of childbearing age and convenient to use and has a broad application prospect. Moreover, the sperm function detection reagent prepared from the C-type natriuretic peptide is adopted for identifying the sperm quality, the operation is simple, the result is easy to observe, a small semen volume is required, and the sperm function detection reagent is suitable for in-vitro detection of sperm function.
The process consists of (a) preparing a lipid soln. in organic solvent, which can contain the active material in soln. (b) evaporating to dryness, leaving a matrix contg. the active ingredient (c) adding an organic solvent for homogenising (d) if the active materials are insoluble in inorganic solvent, dissolving them in a suitable buffer (e) homogenising the heterogeneous mixt. from (d) at 8000-15000 rpm for 15 mins. to obtain a multi-lamellar liposome suspension with particle size 250-350 m and polydispersity 0.17 and (f) opt. subjecting to extrusion to further reduce particle size.
Primary endpoint :Incidence of neurological complications (Transient and Permanent complications; e.g. transient neurological symptoms, arachnoiditis, cauda equina syndrome).Two follow-up questionnaires are foreseen, at 24 h and 7 days after time of spinal injection (Tsp), to gather all possible neurological complications, with particular attention to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome (CES).Patients scheduled for elective surgery will be informed about the aims, procedures and possible risks of the study and will be asked to sign the informed consent form for the inclusion in the trial, from day -14 to day of surgery (visit 1, Day 0).This observational study is planned to collect data on patients undergoing surgery under intrathecal anesthesia with chloroprocaine hydrochloride, primarily to assess the occurrence of all possible neurological adverse events (with particular attention to TNS and CES). The mandatory follow-ups of the study are at 24 h and 7 days (-1/+2) after anaesthesia. In case of signs of neurological complications, the patient has to undergo to a medical visit at the hospital by the relevant specialists (anaesthetist, surgeon, neurologist). In order to characterise the occurred adverse event, a complete analysis evaluation has to be conducted, as CT, MRI, Electromyography, etc. following the indication of the specialists. In case of persistent neuropathy the patient needs to be accurately followed according to the internal hospital procedure. In the meantime, a full screening of the patient's clinical history together with a detailed analysis of the relevant variables, potentially related to the adverse event, have to be carried out.

Therefore, the physician will take all appropriate measures to ensure the safety of the patients, notably he/she should follow up the outcome of any Adverse Events (clinical signs, laboratory values or other, etc.) until the return to normal or consolidation of the patient's condition. In case of any Serious Adverse Event, the patient has to be followed up until clinical recovery is complete and laboratory results have returned to normal, or until progression has been stabilized. The follow-up will continue after the patient has left the study.
A control population (Non RRMS) will include a minimum of 20 age and gender matched healthy patients from the George Washington University (GWU) neurology outpatient clinic (being compared with those RRMS patients being treated with Gilenya® ) for whom Brain MRI's are being ordered as a result of their having headaches, dizziness, or other conditions where there is no physical evidence for neurologic impairment. All control patients will only be recruited by the full time Neurology Faculty at the GWU Medical Faculty Associates (MFA). Control patients will be asked to consent to have NeuroQuant added to their routine Brain MRI which will add 7 minutes to their time in the MRI scanner to obtain additional image data.
Bredent SKY® dental implants were applied at a torque level of 30 N.cm as recommended by the manufacturer. The surgery and all measurements were performed by the same surgeon.
Group 1 consists of breast cancer patients with local or locally advanced disease. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. A subgroup of participants within this group (those who have changed disease or treatment status) will be asked to complete the above questionnaires again, three months later (+-1 week). They will also complete an anchor question. Completing twice is for the responsiveness to change analysis.
This is an exploratory natural history protocol that enrolls patients with known or as yet undiagnosed disorders of inflammation. Blood, saliva, or buccal samples will be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, a small number of subjects may undergo skin biopsy, leukapheresis, or bone marrow aspiration and biopsy, and some subjects will be provided standard medical care follow up, with retrospective analysis of the clinical data gathered during follow up. The primary objective is to discover the genetic basis of human disorders of inflammation. The secondary objective is to enumerate immunologic features and genotype-phenotype associations in specific autoinflammatory diseases. The tertiary objective is to describe the clinical features of poorly characterized or newly defined disorders of inflammation. This protocol provided clinical support for the identification of the gene mutated in familial Mediterranean fever (FMF), the discovery of the TNF receptor-associated periodic syndrome (TRAPS), the identification of NLRP3 mutations in the neonatal-onset multisystem inflammatory disease (NOMID), the discovery of the deficiency of the IL-1 receptor antagonist (DIRA), and the proposal of the now widely accepted concept of autoinflammatory disease. During the last decade the protocol has provided the clinical foundation for the discovery of ten more monogenic autoinflammatory diseases, seven of which were previously unrecognized as distinct diseases. The protocol has also permitted numerous studies delineating the mechanisms of autoinflammation and its connections with the human innate immune system. The work catalyzed by this protocol has provided the conceptual basis for a number of targeted therapies. During the next decade the objective will be to utilize cutting edge genomic technologies to further advance discovery.
BACKGROUND: The role of Platelet-rich Plasma injections as a complementary therapy, together with other minimally invasive procedures, has been analyzed previously, however, there are no articles that evaluate the effects of intra-articular infiltration in the Temporomandibular Joint by itself. The aim of this article is to evaluate the effectiveness of intra-articular infiltration with Platelet-rich Plasma, as a single procedure, to both reduce pain and improve clinical parameters in painful joint disorders.
MATERIAL AND METHODS: A systematic search was performed using the terms "Temporomandibular Joint Disorders" and "Platelet-rich plasma" in May 2021. Only the Clinical Trials found in the Pubmed/Medline, Embase, Cochrane Library/Cochrane CENTRAL, Google Scholar, and LILACS databases were selected.
RESULTS: Only four articles were selected for full-text review. Statistically significant differences were found in pain reduction Platelet-rich Plasma-based interventions with respect to preoperative measurements up to six months. Only two studies found significant intergroup differences favoring Platelet-rich Plasma over other interventions. In relation to maximum mouth opening, three studies reported an increase compared to the preoperative measurements.
CONCLUSIONS: Platelet-rich Plasma might potentially be effective in reducing pain levels and improving clinical parameters such as interincisal distance. However, studies with better methodological quality, larger sample sizes, and lower risk of bias are required to assess the real value of this intervention in the management of painful joint disorders.
To assess the knowledge and attitude of practicing physicians and surgeons towards the use of pain medication according to the World Health Organisation cancer pain analgesic ladder, the current study was conducted at tertiary care hospitals of the four provinces of Pakistan. Professionals having experience of treating cancer patients for >2 years were included. Data was collected using a self-administered questionnaire sent to each participant using Google Forms. Of the 630 physicians approached, 133(21%) responded. Of them, 74(55.64%) participants were familiar with the World Health Organisation analgesic ladder. There was a significant difference in the frequency of using the ladder based on age (p<0.05). Most participants 31(23%) reported the nonavailability of the recommended drugs as the reason for not following the analgesic ladder. There is a strong need to educate physicians and surgeons about the World Health Organisation analgesic ladder, and to make strategies to improve opioid availability in Pakistan.
PURPOSE: The sacroiliac (SI) joint is recognized as a source of low back pain in 15-30% of patients. Though randomized controlled trials have shown clinical improvement following SI joint fusion in 83.1% of patients, revision rates of 2.9% within 2 years have been reported. There is a paucity of literature reviewing this small yet significant population of patients requiring revision surgery.
METHODS: Following IRB approval, retrospective review of patients, who underwent a revision SI joint fusion from 2009 to 2021 was completed. Patient-reported outcomes were measured before and at each clinic visit after surgery with visual analoge scale (VAS) for back pain and Oswestry Disability Index (ODI). Patient characteristics (chronic opiate use and prior lumbar fusion) and surgical factors (operative approach, type/number of implants and use of bone graft) were recorded. Patient-reported outcomes were evaluated with Paired t and Wilcoxon signed rank tests. Univariate and multivariate logistic regression determined if patients met the minimally clinical important differences (MCID) for VAS-back pain and ODI scores at 1 year.
RESULTS: Fifty-two patients (77% female) with an average age of 49.1 (SD ± 11.1) years met inclusion criteria. Forty-four had single sided revisions and eight bilateral revisions. At 1 year follow-up there was no significant improvement in VAS-Back (p = 0.06) or ODI (p = 0.06). Patients with chronic opioid use were 8.5 times less likely to achieve the MDC for ODI scores (OR 0.118, p = 0.029). There was no difference in outcomes when comparing the different surgical approaches (p = 0.41).
CONCLUSION: Our study demonstrates patients undergoing revision surgery have moderate improvement in low back pain, however, few have complete resolution of their symptoms. Specific patient factors, such as chronic opiate use and female sex may decrease the expected improvement in patient-reported outcomes following surgery. Failure to obtain relief may be due to incorrect indications, lack of biologic fusion and/or presence of co-pathologies. Further clinical examination and consistent long-term follow-up, clarify the role revision surgery plays in long-term patient outcomes.